Oncotarget

Research Papers:

The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy

Dongryul Oh, Yong Chan Ahn, Hee Chul Park, Do Hoon Lim, Jae Myoung Noh, Won Kyung Cho and Hongryull Pyo _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:35700-35706. https://doi.org/10.18632/oncotarget.16054

Metrics: PDF 1844 views  |   HTML 2554 views  |   ?  


Abstract

Dongryul Oh1, Yong Chan Ahn1, Hee Chul Park1, Do Hoon Lim1, Jae Myoung Noh1, Won Kyung Cho1, Hongryull Pyo1

1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to:

Hongryull Pyo, email: [email protected]

Keywords: radiotherapy, carcinoma, non-small cell lung cancer, chemoradiotherapy, supraclavicular lymph node metastasis

Received: October 26, 2016     Accepted: February 28, 2017     Published: March 09, 2017

ABSTRACT

Background: This study aimed to investigate the prognostic impact of supraclavicular lymph node (SCN) metastasis in patients who were treated with definitive chemoradiotherapy for N3-IIIB stage non-small cell lung cancer (NSCLC).

Results: The 2- and 5-year overall survival (OS) rates were 57.3% and 35.7% in patients without SCN metastasis and 56.4% and 26.7% in patients with SCN metastasis, respectively. The median OS was 34 months in both groups. There was no significant difference in OS between the two groups (p = 0.679). The 2- and 5-year progression-free survival (PFS) rates were 24.1% and 12.6% in patients without SCN metastasis and 18.0% and 16.0% in patients with SCN metastasis, respectively. Patients without SCN metastasis had slightly longer median PFS (10 months vs. 8 months), but the difference was not statistically significant (p = 0.223). In multivariate analysis, SCN metastasis was not a significant factor for OS (p = 0.391) and PFS (p = 0.149).

Materials and Methods: This retrospective analysis included 204 consecutive patients who were treated with chemoradiotherapy for N3-IIIB stage NSCLC between May 2003 and December 2012. A median RT dose of 66 Gy was administered over 6.5 weeks. Of these, 119 patients (58.3%) had SCN metastasis and 85 (41.7%) had another type of N3 disease: mediastinal N3 nodes in 84 patients (98.8%) and contralateral hilar node in one (1.2%). The patients were divided into two groups according to SCN metastasis.

Conclusions: SCN metastasis does not compromise treatment outcomes compared to other mediastinal metastasis in the setting of definitive chemoradiotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16054